Last reviewed · How we verify
NPH and regular insulin
NPH and regular insulin is a Insulin combination therapy Small molecule drug developed by Riverside University Health System Medical Center. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when other agents are insufficient).
NPH and regular insulin work together to replace or supplement the body's natural insulin, allowing cells to take up glucose and lowering blood sugar levels.
NPH and regular insulin work together to replace or supplement the body's natural insulin, lowering blood glucose by promoting glucose uptake into cells and storage as glycogen. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents are insufficient).
At a glance
| Generic name | NPH and regular insulin |
|---|---|
| Sponsor | Riverside University Health System Medical Center |
| Drug class | Insulin combination therapy |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Regular insulin is a short-acting insulin that begins working within 30 minutes and peaks in 2-4 hours, providing rapid glucose control after meals. NPH (Neutral Protamine Hagedorn) is an intermediate-acting insulin that begins working within 1-2 hours and peaks in 4-12 hours, providing basal glucose control throughout the day. The combination provides both mealtime and background insulin coverage.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (when other agents are insufficient)
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes (PHASE4)
- Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings (PHASE4)
- Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER) (PHASE4)
- Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients. (PHASE4)
- Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2) (NA)
- Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NPH and regular insulin CI brief — competitive landscape report
- NPH and regular insulin updates RSS · CI watch RSS
- Riverside University Health System Medical Center portfolio CI
Frequently asked questions about NPH and regular insulin
What is NPH and regular insulin?
How does NPH and regular insulin work?
What is NPH and regular insulin used for?
Who makes NPH and regular insulin?
What drug class is NPH and regular insulin in?
What development phase is NPH and regular insulin in?
What are the side effects of NPH and regular insulin?
What does NPH and regular insulin target?
Related
- Drug class: All Insulin combination therapy drugs
- Target: All drugs targeting Insulin receptor
- Manufacturer: Riverside University Health System Medical Center — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus
- Indication: Drugs for Type 2 diabetes mellitus (when other agents are insufficient)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing